N@N

CNS Response, Inc.: CNS Response CEO Leonard Brandt to Present at the OneMedPlace Finance Forum

^{Published on 2009-01-12 08:20:10, Last Modified on 2009-01-12 08:21:00 - Market Wire}
 

COSTA MESA, CA--(Marketwire - January 12, 2009) - CNS Response, Inc. (OTCBB: [ CNSO ]) today announced that CEO Leonard Brandt will be presenting at the second annual OneMedPlace Finance Forum, for emerging medical technology companies. The conference is being held January 13 and 14 in San Francisco, at the Sir Francis Drake Hotel, located in San Francisco's Union Square at 450 Powell Street. Mr. Brandt's presentation will take place Tuesday, January 13, at 1:45 p.m.

Mr. Brandt will be discussing the company's innovative technology that produces a personalized medication report for physicians to guide treatment of patients with difficult to treat mental illness. CNS Response is the first company to bring a physiological-based technology to market that helps the doctor answer the question, "What is the right medication for my patient?" This is truly personalized medicine.

"This is an excellent venue for our company, as the Forum's goal is to provide exposure for undiscovered companies in the healthcare sector with market caps below $500 million," commented Brandt. "Equally important," added Brandt, "is the Forum's focus on companies developing and commercializing disruptive technologies that have received limited research coverage in the financial communities."

About CNS Response

CNS Response is a life-sciences data company whose patented system provides treatment guidance to psychiatrists and other physicians for patients with behavioral (mental or addictive) disorders. This technology allows CNS Response to create and provide simple reports ("rEEG® Reports") that specifically guide physicians to treatment strategies based on the patient's own physiology.

rEEG® utilizes traditional electroencephalography (EEG) in conjunction with a normative database and a proprietary clinical (symptomatic) database to identify the following: (1) medication classes most likely to be needed; and (2) medications within these classes with the most probable treatment potential for each patient. Reports are provided to physicians in a relationship analogous to that of a reference laboratory. Prospective, retrospective and field studies of treatment-resistant patients have reported treatment success of 70% or greater in managed care, outpatient psychiatric and residential substance abuse clinical settings.

In addition to providing analytical support to physicians, CNS Response is also an aid to pharmaceutical developers, who can use rEEG to (1) stratify study populations to improve the success of FDA clinical trials; (2) provide insight on effective therapeutic dosing of investigational drugs; (3) identify additional indications for psychiatric medications; (4) provide insight into effective drug combinations; and (5) discover opportunities for decision analytics and support. In addition to these applications, CNS Response continues to investigate the use of rEEG analysis for development of proprietary pharmaceutical opportunities. Visit the company's website at [ www.cnsresponse.com ].